99Tcm-3PRGD2 SPECT/CT分子影像在乳腺癌诊疗中的应用进展

康菁芬; 刘海燕; 李彩红; 师志勇; 康菁芬; 刘海燕; 李彩红; 师志勇

doi:10.3760/cma.j.cn121381-202012038-00040

[1]

Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J ClinCA Cancer J Clin, 2018, 68(6): 394-424. doi: 10.3322/caac.21492

[2]

Folkman J. Tumor angiogenesis: therapeutic implications[J]. N Engl J MedN Engl J Med, 1971, 285(21): 1182-1186. doi: 10.1056/nejm197111182852108

[3]

Miladinova D. Molecular imaging in breast cancer[J]. Nucl Med Mol ImagingNucl Med Mol Imaging, 2019, 53(5): 313-319. doi: 10.1007/s13139-019-00614-w

[4]

刁利梅, 熊小明, 杨成万, 等. 整合素ανβ3、ERK1/2在宫颈鳞癌中的表达及其与血管生成拟态的关系[J]. 现代医药卫生, 2017, 33(3): 343-346. doi: 10.3969/j.issn.1009-5519.2017.03.009
Diao LM, Xiong XM, Yang CW, et al. Expression of αvβ3 integrin and ERK1/2 in cervical squamous cell carcinoma and its relation with vasculogenic mimicry[J]. J Mod MedJ Mod Med, 2017, 33(3): 343-346. doi: 10.3969/j.issn.1009-5519.2017.03.009

[5]

张新超, 边艳珠, 国方娜, 等. ⁹⁹Tc^m-3PRGD₂ SPECT诊断大鼠骨移植瘤[J]. 中国医学影像技术, 2020, 36(2): 206-209. doi: 10.13929/j.issn.1003-3289.2020.02.009
Zhang XC, Bian YZ, Guo FN, et al. ⁹⁹Tc^m-3PRGD₂ SPECT in diagnosis of rat bone graft tumors[J]. Chin J Med Imag TechnolChin J Med Imag Technol, 2020, 36(2): 206-209. doi: 10.13929/j.issn.1003-3289.2020.02.009

[6]

Chakravarty R, Chakraborty S, Dash A. Molecular imaging of breast cancer: role of RGD peptides[J]. Mini Rev Med ChemMini Rev Med Chem, 2015, 15(13): 1073-1094. doi: 10.2174/1389557515666150909144606

[7]

Janssen ML, Oyen WJ, Dijkgraaf I, et al. Tumor targeting with radiolabeled α_vβ₃ integrin binding peptides in a nude mouse model[J]. Cancer ResCancer Res, 2002, 62(21): 6146-6151.

[8]

李万婷. ^99mTc-3PRGD₂ SPECT/CT鉴别诊断乳腺良恶性及与分子分型关系的研究[D]. 太原: 山西医科大学, 2018.

Li WT. The value of ^99mTc-3PRGD₂ SPECT/CT of identify benign and malignant breast lesions and the relationship with molecular subtype[D]. Taiyuan: Shanxi Medical University, 2018.

[9]

王健, 宋秀宇, 徐文贵, 等. 乳腺癌放射性核素分子成像研究进展[J]. 国际医学放射学杂志, 2015, 38(4): 361-365. doi: 10.3874/j.issn.1674-1897.2015.04.Z0411
Wang J, Song XY, Xu WG, et al. The research progress of radionuclide molecular imaging for breast cancer[J]. Int J Radiat Med Nucl MedInt J Radiat Med Nucl Med, 2015, 38(4): 361-365. doi: 10.3874/j.issn.1674-1897.2015.04.Z0411

[10]

Ortiz-Arzate Z, Santos-Cuevas CL, Ocampo-García BE, et al. Kit preparation and biokinetics in women of ^99mTc-EDDA/HYNIC-E-[c(RGDfK)]₂ for breast cancer imaging[J]. Nucl Med CommunNucl Med Commun, 2014, 35(4): 423-432. doi: 10.1097/mnm.0000000000000065

[11]

Chen ZY, Fu FM, Li F, et al. Comparison of [^99mTc]3PRGD₂ imaging and [¹⁸F]FDG PET/CT in breast cancer and expression of integrin α_vβ₃ in breast cancer vascular endothelial cells[J]. Mol Imaging BiolMol Imaging Biol, 2018, 20(5): 846-856. doi: 10.1007/s11307-018-1178-y

[12]

高大鹏. ^99mTc-3P₄-RGD₂与^99mTc-MIBI SPECT显像诊断乳腺癌的价值的对比研究[D]. 长春: 吉林大学, 2015.

Gao DP. ^99mTc-3P₄-RGD₂ scintimammography in the assessment of breast lesions: comparative study with ^99mTc-MIBI[D]. Changchun: Jilin University, 2015.

[13]

马庆杰, 陈滨, 高识, 等. ⁹⁹Tc^m-3P₄-RGD₂与⁹⁹Tc^m-MIBI SPECT显像诊断乳腺癌的对比研究[J]. 中华核医学与分子影像杂志, 2016, 36(2): 184-185. doi: 10.3760/cma.j.issn.2095-2848.2016.02.019
Ma QJ, Chen B, Gao S, et al. ⁹⁹Tc^m-3P₄-RGD₂ scintimammography in the assessment of breast lesions: comparative study with ⁹⁹Tc^m-MIBI[J]. Chin J Nucl Med Mol ImagingChin J Nucl Med Mol Imaging, 2016, 36(2): 184-185. doi: 10.3760/cma.j.issn.2095-2848.2016.02.019

[14]

Zhao ZQ, Yang Y, Fang W, et al. Comparison of biological properties of ^99mTc-labeled cyclic RGD peptide trimer and dimer useful as SPECT radiotracers for tumor imaging[J]. Nucl Med BiolNucl Med Biol, 2016, 43(11): 661-669. doi: 10.1016/j.nucmedbio.2016.02.006

[15]

Wang LJ, Shi JY, Kim YS, et al. Improving tumor-targeting capability and pharmacokinetics of ^99mTc-labeled cyclic RGD dimers with PEG₄ linkers[J]. Mol PharmMol Pharm, 2009, 6(1): 231-245. doi: 10.1021/mp800150r

[16]

Liu L, Song Y, Gao S, et al. ^99mTc-3PRGD₂ scintimammography in palpable and nonpalpable breast lesions[J]. Mol Imaging, 2014, 13(5). DOI: 10.2310/7290.2014.00010.

[17]

王任婕. ^99mTc-3PRGD₂ SPECT/CT显像在乳腺癌中的应用[D]. 长春: 吉林大学, 2013.

Wang RJ. The application of ^99mTc-3PRGD₂ SPECT/CT imaging in the patients of breast cancer[D]. Changchun: Jilin University, 2013.

[18]

梁宏伟. ⁹⁹Tc^m-3PRGD2单光子发射计算机断层显像/CT在乳腺癌诊断中应用评价[J]. 中国药物与临床, 2020, 20(22): 3728-3731. doi: 10.11655/zgywylc2020.22.005
Liang HW. Value of ⁹⁹Tc^m-3PRGD₂ SPECT/CT in diagnosing breast cancer[J]. Chinese Remedies ClinicsChinese Remedies Clinics, 2020, 20(22): 3728-3731. doi: 10.11655/zgywylc2020.22.005

[19]

丁森. ^99mTc-3PRGD₂ SPECT/CT显像评估乳腺病变的临床价值: 对比超声[D]. 苏州: 苏州大学, 2018.

Ding S. The clinical role of ^99mTc-3PRGD₂ SPECT/CT in the diagnosis of breast cancer: a comparison with ultrasound[D]. Suzhou: Soochow University, 2018.

[20]

柳林, 宋研, 高识, 等. ⁹⁹Tc^m-3P₄-RGD₂ SPECT显像在乳腺癌诊断中的应用价值[J]. 中华核医学与分子影像杂志, 2015, 35(6): 498-499. doi: 10.3760/cma.j.issn.2095-2848.2015.06.018
Liu L, Song Y, Gao S, et al. ^99mTc-3PRGD₂ scintimammography in palpable and nonpalpable breast lesions[J]. Chin J Nucl Med Mol ImagingChin J Nucl Med Mol Imaging, 2015, 35(6): 498-499. doi: 10.3760/cma.j.issn.2095-2848.2015.06.018

[21]

Chen GB, Ouyang Z, Wang F, et al. Evaluation of Tc-99m-3PRGD2 integrin receptor imaging in the differential diagnosis of breast lesions and comparison with mammography[J]. Cancer InvestCancer Invest, 2017, 35(2): 108-115. doi: 10.1080/07357907.2016.1270957

[22]

李万婷, 刘海燕, 秦丽军, 等. ⁹⁹Tc^m-3PRGD₂整合素受体显像鉴别乳腺良恶性病变的价值及与超声检查的对比研究[J]. 国际放射医学核医学杂志, 2018, 42(3): 242-247. doi: 10.3760/cma.j.issn.1673-4114.2018.03.009
Li WT, Liu HY, Qin LJ, et al. The evaluation of ⁹⁹Tc^m-3PRGD₂ integrin receptor imaging in the differential diagnosis in benign and malignant breast lesions comparision with ultrasound[J]. Int J Radiat Med Nucl MedInt J Radiat Med Nucl Med, 2018, 42(3): 242-247. doi: 10.3760/cma.j.issn.1673-4114.2018.03.009

[23]

Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017[J]. Ann OncolAnn Oncol, 2017, 28(8): 1700-1712. doi: 10.1093/annonc/mdx308

[24]

刘海燕, 李万婷, 秦丽军, 等. ⁹⁹Tc^m-3PRGD₂ SPECT/CT显像半定量参数与乳腺癌临床病理特征的关系[J]. 中华核医学与分子影像杂志, 2018, 38(12): 786-789. doi: 10.3760/cma.j.issn.2095-2848.2018.12.003
Liu HY, Li WT, Qin LJ, et al. Relationship between the semi-quantitative index of ⁹⁹Tc^m-3PRGD₂ SPECT/CT imaging and clinical pathological features of breast cancer[J]. Chin J Nucl Med Mol ImagingChin J Nucl Med Mol Imaging, 2018, 38(12): 786-789. doi: 10.3760/cma.j.issn.2095-2848.2018.12.003

[25]

欧阳忠, 陈贵兵. ^99mTc-3PRGD2 SPECT/CT显像在乳腺癌分子分型中的应用研究[J]. 中国卫生标准管理, 2018, 9(18): 124-126. doi: 10.3969/j.issn.1674-9316.2018.18.055
Ouyang Z, Chen GB. Study on the application of ^99mTc-3PRGD2 SPECT/CT imaging in the molecular typing of breast cancer[J]. Chin Heal Standard ManagementChin Heal Standard Management, 2018, 9(18): 124-126. doi: 10.3969/j.issn.1674-9316.2018.18.055

[26]

闵楷茵. 乳腺癌显像药物^99mTc-AF7P动物显像和^99mTc-3PRGD2临床应用的研究[D]. 长春: 吉林大学, 2017.

Min KY. Researches on ^99mTc-labelled polypeptide receptor imaging by AF7P in animal models and 3PRGD2 in patients with breast cancer[D]. Changchun: Jilin University, 2017.

[27]

Zhou Y, Shao GQ, Liu S. Monitoring breast tumor lung metastasis by U-SPECT-II/CT with an integrin α_vβ₃-targeted radiotracer ^99mTc-3P-RGD₂[J/OL]. Theranostics, 2012, 2(6): 577−588[2020-12-27]. https://www.thno.org/v02p0577.htm. DOI: 10.7150/thno.4443.

[28]

邵国强. ^99mTc-3P-RGD₂显像定量评价肿瘤整合素αvβ3表达及其应用的实验研究[D]. 南京: 南京医科大学, 2012.

Shao GQ. The study on the quantitive analysis of tumor integrin α_vβ₃ expression level by U-SPECT-CT imaging with integrin αvβ3 targeting radiotracer ^99mTc-3P-RGD₂ and its potent application value[D]. Nanjing: Nanjing Medical University, 2012.

[29]

陈珍英. ^99mTc-3PRGD₂ SPECT显像对乳腺癌及腋窝淋巴结转移的诊断价值[D]. 福州: 福建医科大学, 2016.

Chen ZY. Diagnostic value of ^99mTc-3PRGD₂ SPECT imaging for breast cancer and axillary lymph node metastasis[D]. Fuzhou: Fujian Medical University, 2016.

[30]

Ji SD, Zheng YM, Shao G, et al. Integrin α_vβ₃-targeted radiotracer ^99mTc-3P-RGD₂ useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin α_vβ₃ RGD₂ therapy[J/OL]. Theranostics, 2013, 3(11): 816−830[2020-12-27]. https://www.thno.org/v03p0816.htm. DOI: 10.7150/thno.6989.

[31]

Ji B, Chen B, Wang T, et al. ^99mTc-3PRGD₂ SPECT to monitor early response to neoadjuvant chemotherapy in stage Ⅱ and Ⅲ breast cancer[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2015, 42(9): 1362-1370. doi: 10.1007/s00259-015-3062-1

[32]

Chen QQ, Xie Q, Zhao M, et al. Diagnostic value of ^99mTc-3PRGD₂ scintimammography for differentiation of malignant from benign breast lesions: comparison of visual and semi-quantitative analysis[J]. Hell J Nucl MedHell J Nucl Med, 2015, 18(3): 193-198. doi: 10.1967/s002449910302

[33]

Dorbala S, Kijewski MF, Park MA. Quantitative bone-avid tracer SPECT/CT for cardiac amyloidosis: a crucial step forward[J]. JACC: Cardiovasc ImagingJACC: Cardiovasc Imaging, 2020, 13(6): 1364-1367. doi: 10.1016/j.jcmg.2020.05.005